Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical

Glenn A Phillips1, Kathleen W Wyrwich2, Shien Guo3

  • 1Health Economics and Outcomes Research, Global Market Access, Biogen Idec, 133 Boston Post Road, Weston, MA 02493, USA glenn.phillips@biogenidec.com.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|April 18, 2014
PubMed
Abstract

Insights

A responder definition (RD) for the Multiple Sclerosis Impact Scale (MSIS-29) physical impact subscale (PHYS) was established. A worsening of ≥7.50 points on the MSIS-29 PHYS indicates a clinically significant physical impact change in multiple sclerosis (MS) patients.

Area of Science:

  • Neurology
  • Clinical Research
  • Patient-Reported Outcomes

Background:

  • The Multiple Sclerosis Impact Scale (MSIS-29) assesses physical and psychological functioning in multiple sclerosis (MS) patients.
  • Establishing a clear responder definition (RD) is crucial for interpreting changes in patient-reported outcomes.

Purpose of the Study:

  • To determine the responder definition (RD) for the MSIS-29 physical impact subscale (PHYS).
  • To identify a clinically significant threshold for physical worsening in relapsing-remitting MS (RRMS) patients.

Main Methods:

  • Utilized data from the SELECT clinical trial involving RRMS patients.
  • Employed both anchor-based and distribution-based methods to define the RD for MSIS-29 PHYS.
  • Correlated MSIS-29 PHYS scores with the Expanded Disability Status Scale (EDSS) as a primary anchor.

Main Results:

  • Anchor-based methods suggested RD values between 6.91 and 7.50 for MSIS-29 PHYS.
  • Distribution-based methods yielded RD estimates ranging from 6.24 to 10.40.
  • A threshold of 7.50 was selected as the most appropriate RD for physical worsening, aligning with EDSS changes.

Conclusions:

  • A ≥7.50 point increase on the MSIS-29 PHYS subscale is a practical threshold.
  • This threshold effectively identifies clinically significant physical impact changes in RRMS patients.
  • The established RD enhances the interpretability of MSIS-29 PHYS in clinical trials and practice.